|
rs1057519847
|
|
|
0.060 |
GeneticVariation |
BEFREE |
The epidermal growth factor receptor (EGFR), when carrying an activating mutation like del19 or L858R, acts as an oncogenic driver in a subset of lung tumors.
|
31689114 |
2019 |
|
rs1057519848
|
|
|
0.060 |
GeneticVariation |
BEFREE |
The epidermal growth factor receptor (EGFR), when carrying an activating mutation like del19 or L858R, acts as an oncogenic driver in a subset of lung tumors.
|
31689114 |
2019 |
|
rs121434568
|
|
|
0.060 |
GeneticVariation |
BEFREE |
The epidermal growth factor receptor (EGFR), when carrying an activating mutation like del19 or L858R, acts as an oncogenic driver in a subset of lung tumors.
|
31689114 |
2019 |
|
rs121434569
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Identifying nonsmall-cell lung tumours bearing the T790M EGFR TKI resistance mutation using PET imaging.
|
31132309 |
2019 |
|
rs1057519847
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Interestingly, acute loss of Erbb3 suppressed further growth of established EGFR(L858R)-mediated lung tumors.
|
25596284 |
2015 |
|
rs1057519848
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Interestingly, acute loss of Erbb3 suppressed further growth of established EGFR(L858R)-mediated lung tumors.
|
25596284 |
2015 |
|
rs121434568
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Interestingly, acute loss of Erbb3 suppressed further growth of established EGFR(L858R)-mediated lung tumors.
|
25596284 |
2015 |
|
rs121434569
|
|
|
0.060 |
GeneticVariation |
BEFREE |
In tyrosine kinase inhibitor-resistant lung tumors, rociletinib and AZD9291 are highly active when T790M is present and modestly active when T790M is absent.
|
26058074 |
2015 |
|
rs1057519847
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Finally, we showed that EGFR(L858R)/Rhob(+/+) mice developed mainly diffuse lung tumors with a lepidic pattern, whereas EGFR(L858R)/Rhob(+/-) and EGFR(L858R)/Rhob(-/-) developed a greater number of tumors, and aggressive adenocarcinomas with invasive properties.
|
25320360 |
2014 |
|
rs1057519847
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Pharmacologic inhibition of β-catenin suppressed EGFR-L858R-T790M mutated lung tumor growth, and genetic deletion of the β-catenin gene dramatically reduced lung tumor formation in EGFR-L858R-T790M transgenic mice.
|
25164010 |
2014 |
|
rs1057519848
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Finally, we showed that EGFR(L858R)/Rhob(+/+) mice developed mainly diffuse lung tumors with a lepidic pattern, whereas EGFR(L858R)/Rhob(+/-) and EGFR(L858R)/Rhob(-/-) developed a greater number of tumors, and aggressive adenocarcinomas with invasive properties.
|
25320360 |
2014 |
|
rs1057519848
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Pharmacologic inhibition of β-catenin suppressed EGFR-L858R-T790M mutated lung tumor growth, and genetic deletion of the β-catenin gene dramatically reduced lung tumor formation in EGFR-L858R-T790M transgenic mice.
|
25164010 |
2014 |
|
rs121434568
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Pharmacologic inhibition of β-catenin suppressed EGFR-L858R-T790M mutated lung tumor growth, and genetic deletion of the β-catenin gene dramatically reduced lung tumor formation in EGFR-L858R-T790M transgenic mice.
|
25164010 |
2014 |
|
rs121434568
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Finally, we showed that EGFR(L858R)/Rhob(+/+) mice developed mainly diffuse lung tumors with a lepidic pattern, whereas EGFR(L858R)/Rhob(+/-) and EGFR(L858R)/Rhob(-/-) developed a greater number of tumors, and aggressive adenocarcinomas with invasive properties.
|
25320360 |
2014 |
|
rs121434569
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Pharmacologic inhibition of β-catenin suppressed EGFR-L858R-T790M mutated lung tumor growth, and genetic deletion of the β-catenin gene dramatically reduced lung tumor formation in EGFR-L858R-T790M transgenic mice.
|
25164010 |
2014 |
|
rs121434569
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Rapamycin prevents the development and progression of mutant epidermal growth factor receptor lung tumors with the acquired resistance mutation T790M.
|
24931608 |
2014 |
|
rs1057519847
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Similarly, deficiency of Puma impeded the regression of EGFR(L858R)-driven mouse lung tumors upon inactivation of the EGFR-activating mutant.
|
23532334 |
2013 |
|
rs1057519848
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Similarly, deficiency of Puma impeded the regression of EGFR(L858R)-driven mouse lung tumors upon inactivation of the EGFR-activating mutant.
|
23532334 |
2013 |
|
rs121434568
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Similarly, deficiency of Puma impeded the regression of EGFR(L858R)-driven mouse lung tumors upon inactivation of the EGFR-activating mutant.
|
23532334 |
2013 |
|
rs1057519847
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Using specific and sensitive IHC assays, we analyzed the expression of anaplastic lymphoma kinase (ALK), EGFR L858R, and EGFR E746-A750del mutations in a subset of lung tumors, including those expressing ROS1.
|
22661537 |
2012 |
|
rs1057519848
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Using specific and sensitive IHC assays, we analyzed the expression of anaplastic lymphoma kinase (ALK), EGFR L858R, and EGFR E746-A750del mutations in a subset of lung tumors, including those expressing ROS1.
|
22661537 |
2012 |
|
rs121434568
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Using specific and sensitive IHC assays, we analyzed the expression of anaplastic lymphoma kinase (ALK), EGFR L858R, and EGFR E746-A750del mutations in a subset of lung tumors, including those expressing ROS1.
|
22661537 |
2012 |
|
rs121434569
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Nevertheless, several lines of evidence indicate that the T790M mutation confers growth advantage to cancer cells, and it was shown that mice expressing tetracycline-inducible EGFR transgenes harboring the T790M mutation develop lung tumors.
|
19096299 |
2009 |
|
rs121434569
|
|
|
0.060 |
GeneticVariation |
BEFREE |
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.
|
18093943 |
2007 |